Rafael Holdings Q4 Net Loss Widens Due to Cyclo Acquisition-Related Expenses

Wednesday, Oct 29, 2025 4:38 pm ET1min read

Rafael Holdings reported a wider Q4 net loss due to acquisition-related expenses. The company's interests include clinical and early-stage pharmaceutical companies, a medical device company, and a cannabis company. Rafael also holds investments, including Cyclo Therapeutics, which is developing Trappsol Cyclo. The company has a commercial building in Israel.

Rafael Holdings Q4 Net Loss Widens Due to Cyclo Acquisition-Related Expenses

Comments



Add a public comment...
No comments

No comments yet